Startups
A biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, and for which there are currently limited patient options.
retrophin.com.
retrophin.com.
Overview
Location
United States
Employees
201-500
Total raised
$4M
Founded date
2011
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 22, 2016 | The next Sage? Shkreli partner Ligand puts together another sweet startup package deal for Seelos | San Diego-based Ligand Pharmaceuticals $LGND has created a startup licensing package for a still incipient drug developer, complete with a built-in loan and some modest upfront terms for a pipeline that includes a Phase... |
| Sep 22, 2015 | Turing Pharma Boss Martin Shkreli Defends Massive Price Increase As A Good Thing For Patients | Martin Shkreli — founder of Turing Pharmaceuticals and overnight poster boy for everything that is wrong with the pharmaceutical industry — spent a lot of yesterday defending his 5000% price hike on Daraprim, a drug that treats victims of t... |
| May 7, 2012 | Retrophin Completes $4M Series A Financing | Retrophin, LLC, a New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, has completed its $4m Series A financing. The round was led by MSMB Capital, with participation... |
| May 7, 2012 | Retrophin Picks Up $4M Series A | NEW YORK, NY, Biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, announced completion of its Series A financing. >> Click here for more funding data on Retrophin >>... |
Reviews 0
FAQ about RETROPHIN
When was RETROPHIN founded?
RETROPHIN was founded in 2011.
How much funding has RETROPHIN raised?
RETROPHIN has raised $4M in total across 1 funding round.
What has the press written about RETROPHIN?
Parsers VC has collected 5 articles mentioning RETROPHIN, among them “The next Sage? Shkreli partner Ligand puts together another sweet startup package deal for Seelos” (Sep 22, 2016) and “Turing Pharma Boss Martin Shkreli Defends Massive Price Increase As A Good Thing For Patients” (Sep 22, 2015).
Is RETROPHIN still active?
RETROPHIN is probably closed: its latest activity on Parsers VC dates from Jan 6, 2017.